ContraFect Corp (NASDAQ:CFRX) – Equities research analysts at William Blair issued their Q1 2017 earnings estimates for shares of ContraFect Corp in a research report issued to clients and investors on Wednesday. William Blair analyst Y. Xu anticipates that the firm will post earnings per share of ($0.16) for the quarter. William Blair also issued estimates for ContraFect Corp’s Q2 2017 earnings at ($0.16) EPS, Q3 2017 earnings at ($0.18) EPS, Q4 2017 earnings at ($0.19) EPS, FY2017 earnings at ($0.69) EPS and FY2018 earnings at ($0.83) EPS.

CFRX has been the subject of a number of other research reports. Piper Jaffray Companies set a $5.00 price objective on ContraFect Corp and gave the company a “buy” rating in a research report on Monday, November 21st. Maxim Group reaffirmed a “hold” rating on shares of ContraFect Corp in a research report on Wednesday, March 15th.

Your IP Address:

Shares of ContraFect Corp (NASDAQ:CFRX) opened at 2.00 on Monday. ContraFect Corp has a 52 week low of $1.35 and a 52 week high of $4.12. The stock’s 50 day moving average price is $1.99 and its 200-day moving average price is $2.15. The stock’s market cap is $83.16 million.

Several large investors have recently made changes to their positions in CFRX. Baker BROS. Advisors LP bought a new stake in ContraFect Corp during the third quarter valued at $10,034,000. Spark Investment Management LLC bought a new stake in ContraFect Corp during the third quarter valued at $121,000. Adage Capital Partners GP L.L.C. boosted its stake in ContraFect Corp by 66.7% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,500,000 shares of the company’s stock valued at $6,200,000 after buying an additional 1,000,000 shares during the last quarter. Finally, Opus Point Partners Management LLC bought a new stake in ContraFect Corp during the third quarter valued at $744,000. 46.18% of the stock is owned by institutional investors and hedge funds.

5 Day Chart for NASDAQ:CFRX

Receive News & Stock Ratings for ContraFect Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corp and related stocks with our FREE daily email newsletter.